TY - JOUR
T1 - Induced pluripotent stem cells in Alzheimer's disease
T2 - Applications for disease modeling and cell-replacement therapy
AU - Yang, Juan
AU - Li, Song
AU - He, Xi Biao
AU - Cheng, Cheng
AU - Le, Weidong
N1 - Publisher Copyright:
© 2016 Yang et al.
PY - 2016/5/17
Y1 - 2016/5/17
N2 - Alzheimer's disease (AD) is the most common cause of dementia in those over the age of 65. While a numerous of disease-causing genes and risk factors have been identified, the exact etiological mechanisms of AD are not yet completely understood, due to the inability to test theoretical hypotheses on non-postmortem and patient-specific research systems. The use of recently developed and optimized induced pluripotent stem cells (iPSCs) technology may provide a promising platform to create reliable models, not only for better understanding the etiopathological process of AD, but also for efficient anti-AD drugs screening. More importantly, human-sourced iPSCs may also provide a beneficial tool for cell-replacement therapy against AD. Although considerable progress has been achieved, a number of key challenges still require to be addressed in iPSCs research, including the identification of robust disease phenotypes in AD modeling and the clinical availabilities of iPSCs-based cell-replacement therapy in human. In this review, we highlight recent progresses of iPSCs research and discuss the translational challenges of AD patients-derived iPSCs in disease modeling and cell-replacement therapy.
AB - Alzheimer's disease (AD) is the most common cause of dementia in those over the age of 65. While a numerous of disease-causing genes and risk factors have been identified, the exact etiological mechanisms of AD are not yet completely understood, due to the inability to test theoretical hypotheses on non-postmortem and patient-specific research systems. The use of recently developed and optimized induced pluripotent stem cells (iPSCs) technology may provide a promising platform to create reliable models, not only for better understanding the etiopathological process of AD, but also for efficient anti-AD drugs screening. More importantly, human-sourced iPSCs may also provide a beneficial tool for cell-replacement therapy against AD. Although considerable progress has been achieved, a number of key challenges still require to be addressed in iPSCs research, including the identification of robust disease phenotypes in AD modeling and the clinical availabilities of iPSCs-based cell-replacement therapy in human. In this review, we highlight recent progresses of iPSCs research and discuss the translational challenges of AD patients-derived iPSCs in disease modeling and cell-replacement therapy.
KW - Alzheimer's disease
KW - Cell-replacement therapy
KW - Disease modeling
KW - Drugs screening
KW - Induced pluripotent stem cells
UR - http://www.scopus.com/inward/record.url?scp=84969233464&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969233464&partnerID=8YFLogxK
U2 - 10.1186/s13024-016-0106-3
DO - 10.1186/s13024-016-0106-3
M3 - Review article
C2 - 27184028
AN - SCOPUS:84969233464
SN - 1750-1326
VL - 11
JO - Molecular Neurodegeneration
JF - Molecular Neurodegeneration
IS - 1
M1 - 39
ER -